Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

Speed in Reaching First Clinical Milestone Validates Approach

SAN FRANCISCO, January 22 /PRNewswire/ -- Synosia Therapeutics today announced the successful completion of its first clinical trial, a proof-of-concept study that evaluated new therapeutic options for SYN-111 (rufinamide), a sodium channel blocker. Rufinamide was discovered and developed by Novartis and is currently marketed by Eisai in Europe as a drug to treat a form of epilepsy. This first trial was completed in less than seven months from design to final dosing and less than a year after the rights to rufinamide in mood disorders were obtained from Novartis in an exclusive licensing agreement.

The placebo-controlled, double-blind, three-dose study measured drug effect and pattern of response using quantitative electroencephalography (EEG) in healthy volunteers, who all received each dose plus placebo. After each dose, the subject's brain waves were evaluated over the course of 24 hours, noting quantitative change in each wave and the pattern of the change as an indication of rufinamide activity. The study was conducted in France.

"The data from this study lend support to observations in animal behaviour models and further justify investigation of the effect of rufinamide for mood disorders," said Stephen Bandak, Synosia's Chief Medical Officer. "The study has also helped us select a dose for our Phase 2 trial in general anxiety disorder scheduled to start in the United States later this year."

Rights to SYN111 were obtained by Synosia from Novartis in 2007 in an exclusive worldwide (outside of Japan) licensing agreement to develop and commercialise rufinamide for the treatment of anxiety and other mood disorders. It is estimated that over 62 million people in the United States and the five major European pharmaceutical markets suffer from a form of anxiety. Of those, over nine million suffer from general anxiety disorder.(1, 2)

"Our development approach of
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... GERMANY (PRWEB) May 26, 2015 ... R. Grace & Co. (NYSE: GRA) announces that ... good manufacturing practice (GMP) certification from EXCiPACTâ„¢, an ... of pharmaceutical excipients. , All three ... of pharmaceutical grade excipient silica gels have now ...
(Date:5/26/2015)... , May 26, 2015   Intrexon Corporation ... today that Gregory Frost , Ph.D., Senior Vice President ... Jefferies 2015 Global Healthcare Conference on Wednesday, June 3 rd ... in New York City . ... ) is Powering the Bioindustrial Revolution with Better DNA ™ ...
(Date:5/26/2015)... May 26, 2015   PDI , a ... announced that Oakwood Healthcare in Dearborn, ... winning entry in Delivering the Difference ... display excellence in building collaborative relationships between infection ... healthcare facilities.  Oakwood Healthcare,s infection ...
(Date:5/26/2015)... May 26, 2015 Mr. Kevin Xu , ... President Barack Obama and President Bill Clinton ... of loss of Dr. Rongxiang Xu , Kevin,s father. ... leader ahead of his time, Dr. Xu,s commitment to the ... a legacy that will not be forgotten. As a renowned ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, Beyond A Legend 2
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED ... markets advanced in-vitro diagnostic,products, today announced that it will attend ... to October 31, 2009 in Chengdu,China. , , ... 62nd China International Medical Equipment Fair, Date: ...
... a failed terrorist attack in 2006, plane passengers have not ... airports, leaving some parched at the airport and others having ... in Germany is paving the way to eliminate this necessary ... in IOP Publishing,s Superconductor Science and Technology explains ...
... SAN DIEGO, Oct. 20 NuVasive, Inc. ... developing products for minimally disruptive surgical treatments for the spine, ... 2009. , NuVasive reported third quarter revenue of $94.9 million, ... quarter 2008 and a 7.3% increase over the $88.5 million ...
Cached Biology Technology:China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China 20.2 second test for explosive liquids 2NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 12
(Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
... to visualize more of the arteries in the lungs, ... seeing more may have little impact on the patient's ... 198 patients with suspected pulmonary embolism. About half of ... 100 patients had a single-detector CT examination. The radiology ...
... process that repairs damage to the human genome, ... helped establish a method of gene therapy that ... genes. , The findings are available online in ... process known as homologous recombination, Dr. Matthew Porteus ...
... countries of sub-Saharan Africa are threatened daily by a ... disease is caused by organisms called trypanosomes, which are ... approximately 500,000 people in sub-Saharan Africa, a quarter of ... an exceptional genetic strategy for evading the human immune ...
Cached Biology News:Newer imaging techniques may lead to over-treatment 2Researchers pioneer new gene therapy technique using natural repair process 2Researchers pioneer new gene therapy technique using natural repair process 3Breakthrough System for Understanding Ocean Plant Life Announced 2
I-Ab MHC Class II...
... 60 mm Culture Dishes BD BioCoat Collagen ... with a uniform application of rat tail collagen ... I ,Surface : ECM/attachment factors ... nominal : 60 mm x 15 mm ...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
Biology Products: